Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the overall response rate of patients with Multiple
Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
Phase:
Phase 2
Details
Lead Sponsor:
Caitlin Costello University of California, San Diego